This includes drugs under pre-clinical or clinical development, discontinued drugs, designer drugs or veterinary drugs
Approval is expected in 2026 or 2027 depending on trial results and FDA review
Week 12 (retatrutide ~0.25 mg/week) Reduced appetite within days Sweet-craving reduction commonly reported GI side effects (nausea, occasional vomiting) titrating from baseline Weight loss minimal at this dose
Practical dosing considerations that affect duration How you dose retatrutide influences how long each injection lasts in terms of perceptible effects
Additionally, peptides like SS-31 can also influence growth factors, promoting cellular growth and repair
In addition to aiding weight loss, semaglutide 2.4 mg also enhances eating regulation, lessens food cravings, and lessens the typical rise in appetite that follows substantial weight loss, all of which support continued weight control [112]